Market Signal Briefing

BNB, the native token of the Binance ecosystem, has reached a new milestone, with its market capitalization climbing to approximately $165 billion. This achievement marks one of the most notable performances among large-cap cryptocurrencies in recent months and underscores the growing influence and resilience of the token in the broader crypto market.

Dogecoin struggled to rise above $0.2180 and corrected some gains against the US Dollar. DOGE is now consolidating and might decline below $0.1920.

DOGE price started a fresh downside correction below $0.2050.
The price is trading below the $0.240 level and the 100-hourly simple moving average.
There is a bearish trend line forming with resistance at $0.2025 on the hourly chart of the DOGE/USD pair (data source from Kraken).
The price could aim for a fresh increase if it remains stable above $0.1880.

Dogecoin Price Dips Again
Dogecoin price started a fresh increase after it settled above $0.20, like Bitcoin and Ethereum. DOGE climbed above the $0.2050 resistance to enter a positive zone.

The bulls were able to push the price above $0.2120 and $0.2150. A high was formed at $0.2182 and the price is now correcting gains. There was a move below the 50% Fib retracement level of the upward move from the $0.1788 swing low to the $0.2182 high.

Dogecoin price is now trading below the $0.2050 level and the 100-hourly simple moving average. Besides, there is a bearish trend line forming with resistance at $0.2025 on the hourly chart of the DOGE/USD pair.

Source: DOGEUSD on TradingView.com
If there is another increase, immediate resistance on the upside is near the $0.2025 level. The first major resistance for the bulls could be near the $0.2085 level. The next major resistance is near the $0.2120 level. A close above the $0.2120 resistance might send the price toward $0.2180. Any more gains might send the price toward $0.2250. The next major stop for the bulls might be $0.2320.

More Losses In DOGE?
If DOGE’s price fails to climb above the $0.2085 level, it could start a downside correction. Initial support on the downside is near the $0.1930 level and the 61.8% Fib retracement level of the upward move from the $0.1788 swing low to the $0.2182 high. The next major support is near the $0.1880 level.

The main support sits at $0.1800. If there is a downside break below the $0.1800 support, the price could decline further. In the stated case, the price might slide toward the $0.1665 level or even $0.1650 in the near term.

Technical Indicators

Hourly MACD – The MACD for DOGE/USD is now gaining momentum in the bearish zone.

Hourly RSI (Relative Strength Index) – The RSI for DOGE/USD is now below the 50 level.

Major Support Levels – $0.1930 and $0.1880.

Major Resistance Levels – $0.2085 and $0.2180.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Shiba Inu has restored BONE transfers on Shibarium’s Plasma bridge, re-enabling deposits and withdrawals between Ethereum and the layer-2 network following a security incident that forced a month-long pause. In an October 14 post, core contributor Kaal Dhairya wrote that the “Plasma Bridge is back online for BONE, following a comprehensive review and a series of security enhancements,” adding that users can now bridge BONE “with a safer, stronger, and more resilient experience.”

Shiba Inu Relaunches The Shibarium Bridge
The relaunch comes after Shibarium’s bridge was restricted in mid-September following a validator-key compromise that enabled a malicious exit on the PoS bridge. In a September 21 incident report, Dhairya stated that “on September 12, 2025 at 18:44 UTC, unauthorized validator signing power was used to push a malicious state/exit through the PoS bridge, withdrawing multiple assets,” prompting immediate containment measures and a broader hardening program. The team said at the time it would publish full technical details once it was safe to do so and that “bridging remains restricted during containment/hardening.”

Shibarium’s team is positioning the re-opened BONE bridge as the first step in a phased restoration of services, backed by new policy-level and operational controls. The most visible change for users is a mandatory delay before withdrawals finalize: “All BONE Plasma withdrawals now include a 7-day finalization delay. This buffer gives operators and security teams time to monitor and respond to unusual activity before funds finalize—significantly improving defense without removing user access.” The post frames the delay as reinforcing Plasma’s fraud-resistance guarantees.

Another control introduced at the bridge layer is proactive address blacklisting. According to the team, the new mechanism “lets us flag and block suspicious addresses at the bridge layer,” with the intent of preventing repeat abuse across the ecosystem. The Shiba Inu team also emphasized that critical code changes underwent an external review: “All critical changes were reviewed by Hexens, adding an independent layer of expert scrutiny.” The relaunch followed a validation sequence that included unit tests, end-to-end simulations, deployment on the public testnet (“Puppynet”), and “multi-timeframe” monitoring before production activation.

The October 14 update also addresses a separate strand of the September incident involving KNINE and minor OSCAR token flows. The Shiba Inu team disclosed that the attacker “drained and sold roughly $600 worth of OSCAR tokens from the bridge but ignored the 5 ETH recovery offer for KNINE tokens,” which now remain blacklisted and unusable to the attacker. The previously announced KNINE bounty “has expired,” the team said, but it plans “one final, conditional bounty (amount TBD) for complete return of all KNINE held by attacker-controlled addresses,” stressing that partial returns will not qualify and that terms will appear only on verified channels.

While only BONE is live on the Plasma bridge today, Shibarium signaled a broader roadmap. The team plans “gradual re-enablement for other tokens” and is “finalizing a fair and transparent repayment framework for affected users,” with specifics to be published once doing so would not increase risk. The post underscores a measured posture after the September compromise: “Safety first: We won’t publish specifics that could be gamed while security work is ongoing. Expect measured, verifiable updates.”

Context around the month-long outage highlights the extent of remediation behind the scenes. In late September, Shibarium detailed rotations of validator signers, migrations of contract control to multi-party hardware custody, targeted contract-level protections, live monitoring and exchange coordination, and the engagement of independent security and incident-response specialists. The September 21 update also acknowledged decentralization shortcomings in validator operations and outlined a hardening plan “in progress collaboration with Hexens,” with restoration gated on third-party sign-offs and successful drills on test environments.

For now, the reopening restores a critical path for validators, liquidity providers and users who rely on BONE mobility between Ethereum and Shibarium. As the post concludes, the new safeguards—including blacklisting and the 7-day challenge window—are intended to align the bridge’s user experience with the practical realities of operating a Plasma-style system under adversarial conditions: “Every new safeguard, every extra check, and yes—even the 7-day delay—reflects one core principle: protecting the community.”

At press time, the Shiba Inu (SHIB) token traded at $0.00001060.

Shiba Inu trades at key support zone, 1-week chart | Source: SHIBUSDT on TradingView.com
Featured image created with DALL.E, chart from TradingView.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

The world’s largest Ether digital asset treasury, BitMine, has reportedly bought the dip again as ETH continues to retreat from its August all-time high.

Tom Lee-chaired BitMine Immersion Technologies reportedly scooped up a further 104,336 Ether (ETH) worth around $417 million on Thursday, according to onchain data.

Over the past seven hours, three new wallets received the assets from Kraken and BitGo, reported Lookonchain. BitMine has not publicly confirmed the transactions.

“Despite the crypto market crash, Tom Lee still predicts ETH will hit $10,000 by year-end,” they added.

Earlier this week, Lee and BitMEX co-founder Arthur Hayes doubled down on their prediction that Ether will hit $10,000 this year.

Blockchain intelligence firm Arkham agreed with the findings, stating that three new whale wallets just acquired $75 million in ETH each. “The acquisition patterns match BitMine ETH acquisitions from BitGo,” they said. 

BitMine bought the dip earlier this week following the weekend crypto market rout. On Monday, the firm announced that it acquired 202,037 ETH tokens “over the past few days,” taking advantage of the lower prices.  

“The crypto liquidation over the past few days created a price decline in ETH, which BitMine took advantage of,” said Tom Lee at the time. 

BitMine associated Ether transactions. Source: Arkham
DATs remain unfazed Digital asset treasuries, such as BitMine, appear to be unfazed by the recent crypto market turmoil, using the opportunity to buy the dips. 

BitMine has now reached 50% of its treasury target in just a few months, having accumulated a whopping 3 million ETH, equivalent to 2.5% of the entire supply. 

Its holdings also represent half of the Ether accumulated by all public corporate treasuries, which currently stands at 5.9 million ETH, worth $23.7 billion, according to StrategicEthReserve.

ETH down trend deepens The dip buying comes as Ether markets continue to trend downward. 

ETH fell to $3,945 in late trading on Wednesday, representing a 20% decline from its August all-time high of $4,946.  

It had regained a little composure at the time of writing, trading just above the psychological $4,000 level.

Mirroring chart patterns However, Tom Lee is among many experts and analysts who are confident that Ether will resume its bull run over the next couple of months.

“Ethereum is copying Bitcoin’s 2020-2021 run,” said analyst ‘Rekt Fencer’ before adding “$15,000 for ETH is still on the table this cycle.”

Meanwhile, market analyst ‘Crypto Bullet’ compared chart patterns from Bitcoin (BTC) in 2024 to Ether in 2025, stating that they are “exactly the same pattern,” before predicting an Ether move up to $6,000 to $7,000 this year.

ETH price action looks uncannily similar to Bitcoin’s last year: Source Crypto BulletMagazine: Ethereum’s roadmap to 10,000 TPS using ZK tech: Dummies’ guide

Bitcoin trades near a crucial support between $108,400 and $117,100, a zone that has historically prevented deeper corrections.Long-term holders have sold 300,000 BTC since July 2025, adding sustained sell pressure and limiting upside momentum.Holding above $110,000 could spark a rebound to $112,500, but a drop below $108,000 may trigger structural weakness and extended correction.Bitcoin is currently facing one of its most critical tests in months as its price hovers near a key support level that has repeatedly prevented deeper declines. 

However, investor sentiment and market conditions will now determine whether Bitcoin can sustain this level or risk entering a prolonged correction phase.

Bitcoin Is VulnerableBitcoin’s supply quantiles show that the asset has entered its third instance since late August, where spot prices dipped below the 0.95-quantile price model ($117,100). This level represents holdings where roughly 5% of supply, primarily owned by top buyers, sits at a loss. BTC currently trades within the 0.85–0.95 quantile range ($108,400–$117,100), reflecting a significant retracement from the euphoric phase of recent months.

Sponsored

Sponsored

Without renewed momentum to lift prices back above $117,100, Bitcoin risks sliding toward the lower boundary of this range. Historically, when BTC failed to sustain this critical support zone, extended mid- to long-term corrections followed. A drop below $108,000 would likely signal structural weakness, potentially leading to greater losses as investor confidence wavers.

Want more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here.

Bitcoin Supply Quantiles. Source: GlassnodeThe broader macro environment remains challenging for Bitcoin. Since July 2025, persistent long-term holder (LTH) distribution has restricted upside potential. Data shows that approximately 0.3 million BTC have been offloaded by mature investors over this period, indicating steady profit-taking. This sustained sell-side pressure has limited demand growth and kept volatility elevated.

If the distribution trend continues without new inflows from institutions or retail buyers, Bitcoin could face further consolidation. Demand exhaustion may lead to localized capitulation events or temporary market pullbacks before long-term equilibrium returns. 

Bitcoin LTH Supply. Source: GlassnodeBTC Price Holds StrongBitcoin’s price has remained volatile since July 2025 due to macroeconomic pressure and shifting investor sentiment. Even so, BTC has repeatedly found stability around $110,000, signaling potential resilience.

The next major support lies at $108,000, a historically strong level that has been tested several times before. Holding above this zone could enable a rebound toward $112,500 in the short term, especially if macro conditions improve.

Bitcoin Price Analysis. Source: TradingView
However, if bearish pressure intensifies and selling accelerates, Bitcoin could fall below $110,000. A breakdown under $108,000 would invalidate the bullish-neutral outlook and expose BTC to deeper structural weakness.

Disclaimer

In line with the Trust Project guidelines, this price analysis article is for informational purposes only and should not be considered financial or investment advice. BeInCrypto is committed to accurate, unbiased reporting, but market conditions are subject to change without notice. Always conduct your own research and consult with a professional before making any financial decisions. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

Bitcoin may struggle to sustain its upward trend unless something triggers more excitement among investors, according to Glassnode.

“Without a renewed catalyst to lift prices back above $117.1k, the market risks deeper contraction toward the lower boundary of this range,” Glassnode said in a report published on Wednesday. 

Bitcoin (BTC) is trading at around 5% below the $117,000 level, trading at $110,840 at the time of publication, according to CoinMarketCap.

Bitcoin has declined by 4.19% over the past 30 days. Source: CoinMarketCap“Historically, when price fails to hold this zone, it has often preceded prolonged mid- to long-term corrections,” Glassnode said, pointing out the increase in profit-taking among long-term holders in recent times, which may signal “demand exhaustion.”

Hyblock Capital CEO Shubh Varma told Cointelegraph that he expects a “relatively volatile month,” with potential upside ranging from $116,000 to $120,000. 

Sideways price action is “likely outcome” after a crashHowever, Varma said that while “consolidation is the likely outcome” for Bitcoin following a significant market crash, several indicators still point to potential positive momentum for the cryptocurrency.

“ETFs inflows remain quite high, and spot volume seems healthy,” Hyblock said. Before the wider crypto market crash on Friday, which saw Bitcoin briefly fall to $102,000, US-based spot Bitcoin ETFs had recorded a 9-day inflow streak, amounting to $5.96 billion in inflows, according to Farside data.

Another potential bullish catalyst is the prospect of continued rate cuts from the US Federal Reserve. Rate cuts are typically viewed as bullish for riskier assets, such as cryptocurrencies, as they prompt investors to shift away from traditional investments like bonds and term deposits, which become less attractive in a lower interest rate environment.

According to the CME FedWatch Tool, markets are pricing in about a 95.7% chance of another rate cut at the Fed’s Oct. 29 meeting.

Other indicators suggest “increasingly constructive” rest of the year21Shares crypto research strategist Matt Mena said that with the recent liquidations, policy easing approaching, and structural demand accelerating, the setup into year-end appears “increasingly constructive for digital assets.”

Mena said Bitcoin is setting up for a potential move toward $150,000 “as macro tailwinds and institutional flows continue to align.”

Meanwhile, other analysts are predicting higher values by year-end. BitMEX co-founder Arthur Hayes and Unchained Market Research Director Joe Burnett are forecasting a price of $250,000 by the end of 2025.

Magazine: Sharplink exec shocked by level of BTC and ETH ETF hodling: Joseph Chalom

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

-

Inventive partnership transforms the live streaming experience, allowing viewers to purchase e.l.f. products directly through Twitch streams marking an eyes.lips.first.

OAKLAND, Calif.--(BUSINESS WIRE)--e.l.f. Cosmetics, a brand from e.l.f. Beauty (NYSE: ELF), today announced an innovative partnership with Twitch, powered by Amazon Ads, to become the first brand to run an all-new and native in-stream live-shopping element on the popular streaming service.

e.l.f. Cosmetics, a brand from e.l.f. Beauty (NYSE: ELF), today announced an innovative partnership with Twitch, powered by Amazon Ads, to become the first brand to run an all-new and native in-stream live-shopping element on the popular streaming service.

Share
Building on e.l.f.'s popularity with the Twitch community, this first-of-its-kind collaboration allows viewers to seamlessly purchase e.l.f. products directly through Twitch streams without interrupting their viewing experience. The eyes.lips.first. shoppable element will initially appear on e.l.f.'s official Twitch channel, e.l.f.YOU!

Designed to keep audiences engaged while driving measurable business outcomes, this innovative ad format allows brands to connect with highly-engaged communities, turning authentic creator moments into instant product discovery and conversion — all without disrupting the viewing experience.

“When we launched e.l.f.YOU! on Twitch, our vision was simple yet bold — to meet our community where they play, create and connect. Live Streaming on Twitch has always been about self-expression, and we saw an opportunity to ‘game-up’ the space by bringing beauty into the conversation and creating a safe space for every eye, lip and face,” said Patrick O'Keefe, Chief Integrated Marketing Communications Officer at e.l.f. Beauty. “From the start, e.l.f.YOU! was designed to empower female gamers, celebrate creativity and build confidence at the intersection of makeup and the streaming culture. We didn’t just want to show up on Twitch — we wanted to level it up, amplify voices that were often overlooked and prove that beauty belongs everywhere.”

“Twitch is where communities and creators connect through authentic, live engagement — and now, through shoppable moments," said Sarah Iooss, Head of US Agency, Amazon Ads. "We’re thrilled to partner with e.l.f. to test this innovative new format that keeps viewers immersed in the content they love while discovering and purchasing products in real time. It’s an exciting example of how Amazon Ads is helping brands meet customers in more natural, interactive, and joyful ways.”

e.l.f.’s Patrick O'Keefe will appear at TwitchCon San Diego 2025 on the panel “The Future of Co-Creation: Creator & Brand Team-Ups,” where he will discuss this innovative partnership. This event takes place from October 17-19, 2025, at the San Diego Convention Center.

Since launching its presence on Twitch in 2020, e.l.f. has built a vibrant community through engagement with gamers, beauty enthusiasts and creators. The brand's gaming initiatives have included custom tournaments, creator partnerships and limited-edition product collaborations that celebrate the intersection of gaming and beauty. e.l.f.YOU! on Twitch has become a top-performing channel: 43.3M+ Minutes Watched; 800k+ Chat Messages; 64,400+ Minutes Streamed on e.l.f.YOU!

About e.l.f. Cosmetics

e.l.f. Beauty (NYSE: ELF) is fueled by a belief that anything is e.l.f.ing possible. We are a different kind of company that disrupts norms, shapes culture and connects communities through positivity, inclusivity and accessibility. e.l.f. Cosmetics, our global flagship brand, makes the best of beauty accessible to every eye, lip and face by bringing together the best of beauty, culture and entertainment. Our superpower is delivering universally appealing, premium quality products at accessible prices that are e.l.f. clean and vegan, all double-certified by Leaping Bunny and PETA as cruelty free. We are proud to have products made in Fair Trade Certified™ facilities. Learn more at www.elfcosmetics.com.

More News From e.l.f. Cosmetics

Back to Newsroom

Secures UL and cUL certifications for four types of low- and medium-voltage circuit breakers, reinforcing competitiveness in North America
Global low- and medium-voltage circuit breaker market projected to reach USD 29.2 billion by 2034, growing at a CAGR of 8.8%
"The company plans to expand its presence beyond high-voltage transformers to include low- and medium-voltage circuit breakers in North America."
, /PRNewswire/ -- HD Hyundai Electric has secured UL certification, establishing a foothold to expand its market share in North America's low- and medium-voltage circuit breaker market.

Four models of HD Hyundai Electric’s low- and medium-voltage circuit breakers certified with UL and cUL

HD Hyundai Electric announced on Tuesday, October 14, that four types of its low- and medium-voltage circuit breakers — air circuit breakers (ACB), molded case circuit breakers (MCCB), vacuum circuit breakers (VCB), and magnetic contactors (MC) — have obtained UL (Underwriters Laboratories) and cUL (Canadian UL) certifications, the leading safety standards in the North American market.

The UL certification is a globally recognized mark of safety and quality granted by Underwriters Laboratories, a prominent U.S.-based safety certification organization, following rigorous testing and evaluation of electrical, electronic, and industrial equipment. Although not legally mandatory, UL and cUL certifications are effectively required for electrical products distributed in North America, particularly those with potential safety risks such as fire or electric shock. As such, they play a critical role in ensuring product reliability and enhancing market competitiveness.

Low- and medium-voltage circuit breakers are essential components in power distribution systems, delivering electricity generated at power plants to end users. They ensure stable power supply and protect facilities by interrupting excessive current flow during overloads. Depending on voltage levels, they are widely used across residential, commercial, and industrial applications — representing a large and resilient market closely tied to everyday life.

According to Global Market Insights, the global low- and medium-voltage circuit breaker market is projected to grow from USD 12.2 billion in 2024 to nearly USD 29.2 billion by 2034, representing a compound annual growth rate (CAGR) of 8.8% — a 2.4-fold increase over the decade.

An HD Hyundai Electric official said, "With the acquisition of UL certification, we plan to expand our presence beyond high-voltage transformers — where we have consistently held the top market share in North America — into the broader power distribution equipment sector, including low- and medium-voltage circuit breakers."

Meanwhile, HD Hyundai Electric plans to complete the construction of a new power distribution equipment plant in Cheongju, Korea, by the end of this year, further supporting its expansion in the low- and medium-voltage segment. The new Cheongju plant will feature an advanced smart factory system designed to maximize manufacturing efficiency. Once completed, the facility is expected to double the company's annual production capacity of low- and medium-voltage circuit breakers to approximately 13 million units.

SOURCE HD Hyundai

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Significant progress in bulk RNA sequencing, methylation mapping, multiomics integration, and spatial analyses unlocks research previously out of reach for traditional short read platforms.Leveraging Roche’s SBX technology, Broad Clinical Labs achieved the new GUINNESS WORLD RECORD™ for fastest DNA sequencing technique in under four hours, in collaboration with Roche Sequencing Solutions and Boston Children’s Hospital.Wellcome Sanger Institute joins a growing network of early collaborators using SBX technology, driving new insights in genomics research. Basel, 16 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented major updates on its innovative sequencing by expansion (SBX) technology at the American Society of Human Genetics (ASHG) 2025 Annual Meeting in Boston, USA. Following its recent unveiling, SBX is already being recognized by early evaluators in the sequencing community for its combination of speed, flexibility, and longer reads, which significantly expands research possibilities.

“These advances reflect the strong momentum behind our innovative sequencing technology and its potential to transform genomic research and clinical applications,” said Matt Sause, CEO of Roche Diagnostics. “By combining high throughput, speed and longer read lengths, the SBX technology has the potential to enable research and applications that were previously not feasible. Our collaborations with Broad Institute, the Wellcome Sanger Institute, and others, demonstrate the immense potential of the SBX technology to tackle some of biology’s biggest challenges.”

Breaking a GUINNESS WORLD RECORD™
The impact of the SBX technology was recognised when Broad Clinical Labs broke the GUINNESS WORLD RECORD™ for the fastest DNA sequencing technique to date, using a human genome processed from a DNA sample to a final variant call file (VCF) in less than four hours. This milestone, achieved in collaboration with Roche Sequencing Solutions and Boston Children’s Hospital, surpasses the previous benchmark of five hours and two minutes.

“Breaking the GUINNESS WORLD RECORD is a remarkable achievement,” said Mark Kokoris, inventor of the SBX chemistry and Head of SBX Technology at Roche. “The true impact lies in what this speed and accuracy mean for the scientific community and for deciphering complex diseases like cancer and neurodegenerative conditions.”

Growing collaborations
At ASHG 2025, Roche also announced a new collaboration with the Wellcome Sanger Institute, marking the start of a multi-project evaluation of SBX’s capabilities across a range of research applications. The Wellcome Sanger Institute is evaluating potential benefits from longer reads and very high throughput from the SBX technology for instance in Bulk RNA sequencing to explore previously undetectable features such as certain spliced Isoforms.

The Wellcome Sanger Institute partnership adds to existing collaborations that includes Hartwig Medical Foundation, Genentech, The University of Tokyo and others, as well as the Broad Institute where we previously announced a strategic collaboration to develop and pilot groundbreaking research applications.

Methylation mapping with SBX-Duplex
Roche has also made significant progress in methylation mapping – the process of identifying and analysing chemical modifications called methyl groups that are added to DNA. These modifications act like switches or dimmers, controlling whether genes are turned on, off, or somewhere in between. The research workflow combines SBX-Duplex, a methodology in which both strands of the target DNA are linked in a single read, with a high-fidelity methylation mapping method, TET-assisted pyridine borane sequencing (TAPS), a technology in development by Watchmaker Genomics.

This high efficiency intra-molecular consensus workflow can have significant advantages in research applications, including liquid biopsy-based cancer detection and identification of novel epigenetic biomarkers.

Spatial sequencing
At the University of Tokyo, researchers working in collaboration with Roche leveraged the speed and workflow adaptability of SBX in spatial sequencing analyses of banked lung cancer tissue with about 15 billion reads in just one hour. This approach allowed them to rapidly and accurately map gene expression within tissue samples at high resolution, providing critical insights into the dynamics of cells within a tumor microenvironment.

Target enrichment
Roche also demonstrated a target enrichment method using SBX-Simplex workflow that leverages Unique Molecular Identifiers (UMIs) to produce high throughput and high accuracy reads with very low inputs. This can potentially benefit Oncology research where high depth is typically required.

The above examples highlight SBX’s potential to support multiomics research at scale, by combining the power of rapid sequencing with the ability to analyse multiple layers of biological information. Such breakthroughs are redefining how researchers approach disease biology and interpret the interplay between genetics, transcriptional activity, and epigenomic changes.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] The SBX technology and analysis tools are in development and not commercially available. The content of this material reflects current study results or design goals.

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: [email protected]

Hans Trees, PhD
Phone: +41 79 407 72 58 Sileia Urech
Phone: +41 79 935 81 48 Nathalie Altermatt
Phone: +41 79 771 05 25 Lorena Corfas
Phone: +41 79 568 24 95 Simon Goldsborough
Phone: +44 797 32 72 915 Karsten Kleine
Phone: +41 79 461 86 83 Kirti Pandey
Phone: +49 172 6367262 Yvette Petillon
Phone: +41 79 961 92 50 Dr Rebekka Schnell
Phone: +41 79 205 27 03   Roche Investor Relations

Dr Bruno Eschli
Phone: +41 61 68-75284
e-mail: [email protected] Dr Sabine Borngräber
Phone: +41 61 68-88027
e-mail: [email protected] Dr Birgit Masjost
Phone: +41 61 68-84814
e-mail: [email protected]   Investor Relations North America

Loren Kalm
Phone: +1 650 225 3217
e-mail: [email protected]  

Media & Investor Release ASHG SBX World Record English

OMAHA, Neb.--(BUSINESS WIRE)--ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology, today announced a strategic partnership with BitPay, the world’s leading cryptocurrency payments processor, to further expand its digital assets solutions for merchants and payment service providers (PSPs) through ACI's Payments Orchestration Platform.

Our partnership with BitPay represents one element of our broader digital assets strategy. Based on growing demand from our PSPs and merchant clients, we're ensuring they have multiple pathways to leverage these emerging rails where they add value.

Share
This partnership strengthens ACI’s commitment to digital currency innovation by expanding the platform’s established capabilities for merchants and PSPs. According to a recent study by ACI Worldwide and Payments Dive, 55% of global retailers are evaluating cryptocurrency acceptance as part of their payment strategy.

By integrating BitPay, ACI further differentiates its Payments Orchestration Platform, enabling seamless acceptance and management of digital currencies including stablecoins as a strategic complement to traditional payment rails. Building on capabilities ACI introduced in 2021, merchants and PSPs can now integrate BitPay, alongside other payment options to access upgraded features - including the ability to accept, store, and spend cryptocurrencies. BitPay's platform supports a range of use cases, including peer-to-peer payments, and mobile point-of-sale applications.

"As regulated stablecoins evolve from niche to mainstream, they're creating new opportunities for cross-border transactions and settlement optimization," said Adriana Iordan, Global Head of Merchant at ACI Worldwide. "Our partnership with BitPay represents one element of our broader digital assets strategy. Based on growing demand from our PSPs and merchant clients, we're ensuring they have multiple pathways to leverage these emerging rails where they add value - whether for payment acceptance or specific use cases like cross-border B2B settlements and treasury operations."

"Together with ACI Worldwide, we're making digital currencies more accessible and practical for real-world commerce," said Stephen Pair, Co-Founder and CEO at BitPay. "This partnership brings our proven crypto payment capabilities to ACI's global customer base, enabling everything from simple payment acceptance to cross-border settlement scenarios as market demand develops."

The integrated solution supports settlement in both fiat and stablecoins, offering enhanced flexibility and efficiency for merchants operating in diverse markets. As our clients explore these capabilities, businesses can leverage stablecoins for treasury operations, supplier payments, and cross-border settlements - creating new options for how global commerce can operate.

ACI's Payment Orchestration Platform streamlines the complexity of managing multiple payment methods, acquirers, and gateways through a single, unified interface. By incorporating various digital currency solutions, merchants and PSPs can explore new revenue opportunities - typically seeing a 1–3% percent growth in sales where implemented - while offering customers greater choice and convenience at checkout.

“ACI Worldwide remains committed to a rail-agnostic approach, expanding its digital assets ecosystem through additional partnerships and integrations as the market matures,” continued Adriana Iordan. “This ensures our clients are prepared to leverage digital payment innovations as use cases emerge and regulatory frameworks solidify.”

About ACI Worldwide

ACI Worldwide, an original innovator in global payments technology, delivers transformative software solutions that power intelligent payments orchestration in real time so banks, billers, and merchants can drive growth, while continuously modernizing their payment infrastructures, simply and securely. With 50 years of trusted payments expertise, we combine our global footprint with a local presence to offer enhanced payment experiences to stay ahead of constantly changing payment challenges and opportunities.

About BitPay

Founded in 2011, BitPay is one of the oldest cryptocurrency companies. As a pioneer in blockchain payment processing, the company's mission is to transform how businesses and people send, receive, and store money. Its business solutions eliminate fraud chargebacks, reduce the cost of payment processing, and enable borderless payments in cryptocurrency, among other services. For consumers, the BitPay Wallet offers a complete digital asset management solution to buy, store, swap, sell, and spend cryptocurrency with ease. The company has offices in North America, Europe, and South America and has raised more than $70 million in funding from leading investment firms including Founders Fund, Index Ventures, Virgin Group, and Aquiline Technology Growth. For more information visit bitpay.com.

© Copyright ACI Worldwide, Inc. 2025

ACI, ACI Worldwide, ACI Payments, Inc., ACI Pay, Speedpay and all ACI product/solution names are trademarks or registered trademarks of ACI Worldwide, Inc., or one of its subsidiaries, in the United States, other countries or both. Other parties’ trademarks referenced are the property of their respective owners.

The logo of German pharmaceuticals company Merck is seen at the company's headquarters in Darmstadt, Germany, May 16, 2016. REUTERS/Kai Pfaffenbach/File Photo Purchase Licensing Rights, opens new tab

Oct 16 (Reuters) - German pharmaceuticals and technology company Merck KGaA

(MRCG.DE), opens new tab slightly improved its mid-term guidance for its healthcare business ahead of its capital markets day on Thursday.

Merck now expects mid-term annual organic sales growth in the low- to mid single-digit percentage range for its healthcare business, having guided for "slight growth" last year. It expects mid-to-high single-digit percentage growth for Life Science, after guiding for 7% to 9% last year.

Sign up here.

The company also confirmed that it is aiming to achieve net sales between around 20.5 to 21.7 billion euros in 2025, a target it has cut twice this year.

This is far below the 25 billion euros the Darmstadt-based firm had previously guided for at its capital markets day in 2021.

"We had made a number of assumptions on the pandemic that never materialized," Merck's Chief Executive Belen Garijo said in an interview.

The company's life science business was affected by a "Covid cliff" where mRNA vaccines were not in demand for as long as expected, she said.

Reporting by Marleen Kaesebier, Patricia Weiss and Matthias Inverardi; editing by Matt Scuffham

Our Standards: The Thomson Reuters Trust Principles., opens new tab

SummaryChipotle aims to expand from 3,750 to over 7,000 North American locations and is pursuing international growth despite uncertain global demand for Mexican cuisine.CMG is improving operational efficiency with new staff roles and kitchen technology, enhancing customer service speed and employee retention.The company is piloting catering services, which could significantly boost profitability if scaled successfully without disrupting core operations.Risks include weaker lower-income consumer spending and potential stock market declines, which could impact CMG's sales and valuation. Anne Czichos/iStock Editorial via Getty Images

Introduction: Chipotle (NYSE:CMG) is an incredibly popular fast-casual restaurant chain that has taken the United States by storm over the past couple of years. I believe that, despite some near term headwinds such as

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in CMG over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years1

eGFR is key marker of kidney function; IgAN is progressive autoimmune kidney disease that leads to kidney failure in many patients1-3 

Fabhalta is first and only approved complement inhibitor for adults with IgAN and has potential to delay disease progression4,5 

Fabhalta received accelerated approval for reduction of proteinuria in adults with IgAN in US in 2024; data support 2026 submission for traditional FDA approval4,5  Basel, October 16, 2025 – Novartis today announced positive final results from APPLAUSE-IgAN, a Phase III study evaluating Fabhalta® (iptacopan) in adults living with IgA nephropathy (IgAN). Fabhalta, an oral alternative complement pathway inhibitor, demonstrated statistically significant, clinically meaningful superiority compared to placebo in slowing IgAN progression measured by annualized total slope of estimated glomerular filtration rate (eGFR) decline over two years1.  

“Progressive diseases such as IgAN present an urgent need for interventions that can ultimately improve kidney health. Many people with IgAN commonly experience fear and anxiety of disease progression,” said Ruchira Glaser, Development Unit Head, Cardiovascular, Renal & Metabolic, Novartis. “We are excited about today’s positive Phase III APPLAUSE-IgAN results showing slowed eGFR decline, which add to the growing evidence of Fabhalta as a targeted therapy to preserve long-term kidney function, giving hope to people living with this condition.” 

Novartis intends to use these data to support Fabhalta submissions in 2026. Alongside Fabhalta, Novartis continues to advance its multi-asset IgAN portfolio, which also includes Vanrafia® (atrasentan) and investigational compound zigakibart.

IgAN is a progressive autoimmune kidney disease with approximately 25 per million people newly diagnosed worldwide each year3. IgAN is highly debilitating as it leads to glomerular inflammation, proteinuria, and a gradual decline in eGFR2. Up to 50% of patients with persistent proteinuria progress to kidney failure within 10 to 20 years of diagnosis, often requiring dialysis or kidney transplantation as part of long-term disease management2,6,7. Furthermore, people living with IgAN often face mental, social, and economic challenges2,8. Supportive care does not address the underlying causes of the disease and often fails to slow disease progression, reinforcing the need for more targeted therapies for IgAN3,9.

In APPLAUSE-IgAN, Fabhalta was well tolerated with a favorable safety profile in line with previously reported data10. Full data from the APPLAUSE-IgAN final analysis will be presented at future medical meetings.

About Fabhalta® (iptacopan) 
Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway10.

Discovered at Novartis, Fabhalta received US Food and Drug Administration (FDA) and European Commission (EC) approval in December 2023 and May 2024, respectively, for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). Fabhalta also received accelerated approval in the US in August 2024, and in China in September 2025, for the reduction of proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progression (generally UPCR ≥1.5 g/g4,5,11,12. In 2025, Fabhalta received FDA and EC approval as well as approvals in China and Japan for the treatment of adults with C3 glomerulopathy (C3G), making it the first treatment approved for this condition13-15. 

Fabhalta is being studied in a broad range of rare kidney diseases, including atypical hemolytic uremic syndrome (aHUS), immune complex membranoproliferative glomerulonephritis (IC-MPGN) and lupus nephritis (LN)16-18. Studies are ongoing to evaluate the safety and efficacy profiles in these investigational indications and support potential regulatory submissions16-18. 

About APPLAUSE-IgAN 
APPLAUSE-IgAN (NCT04578834) is a Phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of twice-daily oral Fabhalta (200 mg) in 477 adult primary IgAN patients (main study population). Patients were randomized to Fabhalta or placebo, on top of supportive care (a stable dose of maximally-tolerated renin-angiotensin system (RAS) inhibitor therapy with or without a stable dose of SGLT2i)1.    

The two primary endpoints of the study for the interim and final analysis, respectively, are proteinuria reduction at 9 months as measured by UPCR, and the annualized total eGFR slope over 24 months10,18. During the final analysis, the following secondary endpoints were assessed: proportion of participants reaching UPCR <1 g/g without receiving corticosteroids/immunosuppressants or other newly approved drugs or initiating new background therapy for treatment of IgAN or initiating kidney replacement therapy (KRT), time from randomization to first occurrence of composite kidney failure endpoint event (reaching either sustained ≥30% decline in eGFR relative to baseline or sustained eGFR <15 mL/min/1.73 m2 or maintenance dialysis or receipt of kidney transplant or death from kidney failure), and change from baseline to 9 months in the fatigue scale measured by the Functional Assessment Of Chronic Illness Therapy-Fatigue questionnaire19.    

The main study population enrolled patients with an eGFR ≥30 mL/min/1.73 m2 and UPCR ≥1 g/g at baseline10,18. In addition, a smaller cohort of patients with severe renal impairment (eGFR 20–30 mL/min/1.73 m2 at baseline) was also enrolled to provide additional information but not contributing to the main efficacy analyses10,19. 
    
Novartis commitment to kidney diseases 
Building on a 40-year legacy that began in transplant, Novartis is on a mission to empower breakthroughs and transform care in kidney health, starting with kidney conditions that have significant unmet need.  

Historically, these conditions have had considerably less funding and research, leading to a treatment landscape largely focused on reactive or end-stage disease management, often with significant physical, emotional, and financial burdens. Our portfolio targets the underlying causes of disease, with an aim to protect kidney health and delay or prevent dialysis and/or transplantation. Our goal is to help patients get back to living life on their terms - whether at work, in school, or with loved ones, and by partnering with patients, advocates, clinicians and policymakers, we aim to raise awareness, accelerate diagnosis and get patients the right care, sooner.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis 
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

References

Novartis. Data on file. Kwon CS, Daniele P, Forsythe A et al. A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin a nephropathy. J Health Econ Outcomes Res 2021;8:36–45. Cheung C, Barratt J. The rapidly changing treatment landscape of IgA nephropathy. Semin Nephrol 2025;44:151573. Novartis Pharmaceuticals Corporation. Fabhalta prescribing information. 2023 (2025 update). Available at: https://www.novartis.com/us-en/sites/novartis_us/files/fabhalta.pdf (accessed October 2025). Novartis Pharmaceuticals Corporation. Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN) (2024). Available at: https://www.novartis.com/news/media-releases/novartis-receives-fda-accelerated-approval-fabhalta-iptacopan-first-and-only-complement-inhibitor-reduction-proteinuria-primary-iga-nephropathy-igan (accessed October 2025). Pitcher D, Braddon F, Hendry B et al. Long-term outcomes in IgAN. Clin J Am Soc Nephrol 2023;18:727–8.Mohd R, Mohammad Kazmin NE, Abdul Cader R, et al. Long-term outcome of immunoglobulin A (IgA) nephropathy: a single center experience. PLoS One. 2021;16:e0249592. National Kidney Foundation. The voice of the patient (2020). Available at: https://igan.org/wp-content/uploads/2021/01/VOP_IgAN_12-7-20__FNL.pdf (accessed October 2025).Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100:S1–276. Perkovic V, Barratt J, Rovin B, et al. Alternative complement pathway inhibition with iptacopan in IgA nephropathy. N Engl J Med. 2025;392:531–543.Fabhalta®. EMA Summary of Product Characteristics. Novartis Europharm Limited (2024). Available at: https://www.ema.europa.eu/en/documents/product-information/fabhalta-epar-product-information_en.pdf (accessed October 2025). PHARMCUBE. Novartis expands indications for iptacopan, capmatinib in China (2025). Available at: Novartis Expands Indications for Iptacopan, Capmatinib in China PharmCube-News & Reports (accessed October 2025). Fineline Cube. Novartis’ fabhalta approved in China for C3 glomerulopathy (2025). Available at: Novartis' Fabhalta Approved in China for C3 Glomerulopathy - Insight, China's Pharmaceutical Industry (accessed October 2025). Pharma Japan. Novartis makes full foray into nephrology space with fabhalta: exec (2025). Available at: Novartis Makes Full Foray into Nephrology Space with Fabhalta: Exec | PHARMA JAPAN (accessed October 2025).Novartis. Press release. Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) (2025). Available at: https://www.novartis.com/news/media-releases/novartis-receives-third-fda-approval-oral-fabhalta-iptacopan-first-and-only-treatment-approved-c3-glomerulopathy-c3g (accessed October 2025). Clinicaltrials.gov. NCT04889430. Efficacy and Safety of Iptacopan (LNP023) in Adult Patients with Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy (APPELHUS). Available at: https://clinicaltrials.gov/study/NCT04889430 (accessed October 2025).  Clinicaltrials.gov. NCT05755386. Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN (APPARENT). Available at: https://clinicaltrials.gov/study/NCT05755386 (accessed October 2025). Clinicaltrials.gov. NCT05268289. Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/ - V. Available at: https://clinicaltrials.gov/study/NCT05268289 (accessed October 2025). Rizk DV, Rovin BH, Zhang H et al. Targeting the alternative complement pathway with iptacopan to treat IgAN: design and rationale of the APPLAUSE-IgAN study. Kidney Int Rep 2023;8:968–79.  # # #

SummaryI believe Palantir's UK strategic partnership should catalyze international government growth from future NATO and European MoD wins.Considering the momentum in the number of deals announced since PLTR's last earnings season (7 at the moment of writing this article), I see a high-probability Q3 and FY25 beat.Despite robust US commercial growth, international commercial revenue remains weak, hindered by EU AI regulations and a lack of new deals.I am now ultra-bullish on PLTR, expecting the company to outperform Street estimates in Q3 and maintain its upward trajectory. merc67/iStock via Getty Images

In my last coverage on Palantir Technologies Inc. (NASDAQ:PLTR) (NEOE:PLTR:CA), I was quite cautious with my bull thesis, given that I estimated that 76% of cRPO depends on cancelable sub-12-month contracts.

Since then, I've been keeping

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Elon Musk’s one-word reply on X has put Bitcoin back in the headlines, even if the comment was brief. His simple response — “True” — came after a widely shared post linking recent gains in gold, silver and Bitcoin to heavy government spending and currency debasement. Markets and crypto fans noticed fast.

Musk’s Brief Reply Signals Interest
According to the post by ZeroHedge, which has more than 2 million followers, the rallies were tied to what the author called an AI “arms race” between the US and China and to large-scale fiscal outlays.

Musk agreed with the thread. He added a view that echoes a common pro-Bitcoin line: fiat can be printed, while Bitcoin’s tie to energy gives it a different kind of backing. That single-word answer reopened a conversation many thought had cooled.

The money is not the problem: AI is the new global arms race, and capex will eventually be funded by governments (US and China). If you want to know why gold/silver/bitcoin is soaring, it’s the “debasement” to fund the AI arms race.

But you can’t print energy https://t.co/qwdD8QbVON

— zerohedge (@zerohedge) October 14, 2025

True.

That is why Bitcoin is based on energy: you can issue fake fiat currency, and every government in history has done so, but it is impossible to fake energy.

— Elon Musk (@elonmusk) October 14, 2025

Tesla’s Past Moves And Holdings
Based on reports, Tesla bought $1.5 billion of Bitcoin in early 2021 and said it would take the coin as payment for cars. But the deal was short-lived.

The company soon stopped accepting Bitcoin because of concerns about mining’s heavy energy use and said it might resume payments only after a major move toward renewable mining practices.

By mid-2022, Tesla sold about 75% of its holdings, a move that happened near a market low and drew wide notice. According to Arkham Intelligence, Tesla still holds roughly 11,509 BTC, which is worth about $1.25 billion at current prices.

BTCUSD now trading at $111,517, Chart: TradingView
What The Market Might Be Watching
Traders read signals. A single public endorsement from a high-profile executive used to move prices more. That was the case in 2021 when Tesla’s investment and payment plan helped lift sentiment.

Now, the context is different. Crypto markets are bigger and more diverse, and a one-word message does not equal a corporate decision. No official change at Tesla has been reported, and company spokespeople have not confirmed any shift in strategy.

Featured image from ET Edge Insights, chart from TradingView

Leading cryptocurrencies fell on Wednesday, but stocks recovered, as the Trump administration remained resolute in its stance against China.

CryptocurrencyGains +/-Price (Recorded at 9:30 p.m. ET)Bitcoin (CRYPTO: BTC)-1.48%$110,900.78Ethereum (CRYPTO: ETH)
               -2.29%$3,995.86XRP (CRYPTO: XRP)                         -3.41%$2.41Solana (CRYPTO: SOL)                         -4.15%$194.27Dogecoin (CRYPTO: DOGE)                         -3.37%$0.1969Crypto Market FaltersBitcoin meandered in the $111,000 region as trading volume declined sharply. Spot exchange-traded funds linked to the asset recorded net outflows of more than $90 million on Oct. 15, according to SoSo Value.

Ethereum dipped below $4,000 but found good support in the $3,900 zone. Trading volume declined 27% over the last 24 hours. XRP and Dogecoin also edged lower.

Cryptocurrency liquidations reached $442 million in the last 24 hours, with nearly $400 million in long positions wiped out from the market, according to Coinglass. That said, nearly $500 million in BTC shorts risked liquidation if the asset rebounds to $115,000

Bitcoin’s open interest declined 1.77% in the last 24 hours, and more than 23% since the all-time highs hit earlier this month.

"Fear" sentiment continued to define the market, according to the Crypto Fear & Greed Index.

Top Gainers (24 Hours) 

Cryptocurrency (Market Cap>$100 M)Gains +/-Price (Recorded at 9:30 p.m. ET)Bless (BLESS)     +591.90%$0.2165BNB Attestation Service (BAS)    
               +56.14%$16.65ChainOpera AI (COAI )          +19.48%$0.7964The global cryptocurrency market capitalization stood at $3.75 trillion, following a decrease of 2.24% in the last 24 hours.

Stocks Rebound, Gold StrengthensThe stock market bounced back on Wednesday. The S&P 500 gained 0.4% to close at 46,253.31, while the tech-focused Nasdaq Composite ended up 0.7% at 22,670.08. The Dow Jones Industrial Average inched lower, sliding 17.15 points, or 0.04%, to end at 46,253.31.

The recovery came despite Treasury Secretary Scott Bessent stating that the recent sell-offs won't deter Washington from taking "strong measures" against China.

Last week, Trump threatened "100% tariffs" on China over its "aggressive" stance on export controls, sending stocks and cryptocurrencies crashing.

Meanwhile, gold continued its record-breaking run, surging past $4,200 per ounce.

Why ETH Should Hold This LevelWidely followed cryptocurrency analyst and trader Ali Martinez highlighted $3,900 as a "major support zone" for Ethereum.

"Iff it holds, the Pricing Bands point to a move toward $5,000 or even $6,000," Martinez predicted.

The Market Value Realized Value Deviation Pricing Bands model price levels based on deviations from its realized price and help identify market cycle tops and bottoms.

Blockchain analytics firm CryptoQuant said that Bitcoin has moved into the later stage of its bull cycle, with long-term investors booking profits while short-term holders taking control. 

"The key signal to watch next will be a decline in short-term holder share, which would mark the start of a renewed accumulation phase led by long-term investors," CryptoQuant added.

Photo Courtesy: Travis Wolfe on Shutterstock.com

Read Next:    

Bitcoin, Ethereum, Tesla On 5x Steroids: VolatilityShares Seeks SEC Approval For Its Wildest Ride Yet
Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

3 mins mins

Key Points:

UK authorities seized 61,000 BTC in major fraud case.$6.8 billion Bitcoin scam victims await compensation plan.Legal debates continue over Bitcoin fund retention or compensation.
British prosecutors announced plans to compensate victims of Zhimin Qian’s nearly $7 billion Bitcoin scam in China, seized by UK authorities between 2018 and 2021.

The case highlights ongoing legal debates over asset allocation in fraud scandals, with potential impacts on international regulatory practices and crypto market stability.

UK Seizes 61,000 BTC in Historic Recovery Amid Scam
In a major development, authorities in the United Kingdom are preparing to offer compensation to victims of a significant Bitcoin scam that defrauded over 128,000 individuals in China. During the period from 2014 to 2017, Zhimin Qian orchestrated a series of fraudulent investment schemes, converting the ill-gotten gains into nearly $7 billion worth of Bitcoin.

Bitcoin valued at $6.8 billion, or 61,000 BTC, has been seized, marking one of the largest asset recovery cases globally. The UK government is currently deliberating on the use of these assets, which may support victim restitution or be retained under specific asset forfeiture laws.

Reactions to the case have sparked considerable debate. Jackson Ng, representing investors, emphasized the importance of prioritizing victims’ compensation in light of the substantial assets involved. Meanwhile, Nick Harris of CryptoCare has expressed concerns that UK authorities might keep the funds, potentially frustrating expectations for compensation.

Jackson Ng, Legal Representative, stated, “We are prioritizing victim compensation, though the specifics of the plan are still to be determined.” – source
Bitcoin Price and Legal Proceedings Stir Market Concerns
Did you know? The seizure of 61,000 BTC in the Zhimin Qian case surpasses the historic Silk Road BTC recovery, setting a new precedent in asset seizure operations globally.

Bitcoin (BTC), currently priced at $111,436.30, shows a market cap of $2.22 trillion. With a 24-hour trading volume of $70.73 billion, the BTC market faced a decrease of 1.58% over the last day, as reported by CoinMarketCap. Its 90-day price change reflects a loss of 7.26% amidst these developments.

Bitcoin(BTC), daily chart, screenshot on CoinMarketCap at 02:26 UTC on October 16, 2025. Source: CoinMarketCap

Coincu analysts note the ongoing legal proceedings could influence regulatory approaches towards crypto asset retention and redistribution. Past cases show assets are typically retained, raising questions on future compensation guidelines and jurisdictional asset management. For more insights, UK prosecutors pursuing compensation plan for record Bitcoin seizure offers additional context. The case also accentuates the need for a robust legal framework to manage such seizures, as highlighted by similar scenarios discussed in analyses like this report on Bitcoin trends.

DISCLAIMER: The information on this website is provided as general market commentary and does not constitute investment advice. We encourage you to do your own research before investing.

Rate this post

Coinbase has revealed plans to list BNB on its platform as part of its listing roadmap.

Massive DOJ seizure, $1.3B wallet move, and 401(k) bill fuel bullish rebound — Bitcoin price prediction eyes $130K breakout.

Journalist

Posted: October 16, 2025

Key Takeaways
What’s driving Zcash’s rebound?
ZEC rose 12% after Open Interest hit $237 million, signaling renewed leverage activity and strong retail buying pressure.

How high can it go?
Sustained demand above $250 could push ZEC past $300, with momentum building toward its $391 all-time high.

Zcash [ZEC] rebounded sharply over the past 24 hours, gaining 12% from its recent dip at press time, and reignited investor attention.

The daily chart showed that the broader trend remained bullish, with $298 as the next key resistance target.

In fact, the Stochastic RSI approached the oversold zone near 30, hinting that the latest rebound could mark the end of the short-term correction.

That left traders watching whether ZEC’s bullish spark could evolve into a sustained rally.

Source: TradingView

Leverage piles up as Open Interest hits $237M
According to data from Coinalyze, ZEC’s Open Interest (OI) climbed by 10% in the past day, reaching $237 million.

The uptick reflected a surge in leveraged positions and speculative inflows, a familiar sign of traders rushing to capitalize on short-term momentum.

From the previous observations, such spikes tend to precede volatile phases as markets adjust to overextended leverage, making the next few sessions critical for ZEC’s direction.

Source: Coinalyze

At the same time, ZEC retail traders have been particularly active, driving liquidity and fueling optimism across exchanges.

Accumulation clusters formed around current price levels, suggesting that smaller investors were fueling liquidity. That behavior mirrored previous altcoin rallies, where early retail inflows typically preceded larger institutional entries.

If ZEC sustains its current accumulation, the altcoin could attract institutional attention once again.

Source: CryptoQuant

Spot strength vs. speculative fragility
While the momentum looked promising, the sustainability of ZEC’s move hinges on more than short-term enthusiasm.

For your understanding, leverage-driven rallies can quickly lose steam if they lack follow-through from spot market buyers or long-term holders.

Data from CryptoQuant showed both Spot Taker CVD and Futures Taker CVD in Taker Buy Dominant territory, confirming active demand.

Yet, sustained upside required deeper participation from whales and institutions.

Source: CryptoQuant

On top of that, maintaining support around the breakout zone remained critical. A strong defense there could keep momentum intact toward $300.

If OI and spot demand continue rising together, ZEC could retest $300 and possibly aim for its next psychological mark near $391, its all-time high.

Ethereum price is still struggling to settle above $4,220. ETH is now consolidating in a range and might decline sharply if there is a move below $3,880.

Ethereum started a recovery wave above the $4,000 and $4,020 levels.
The price is trading below $4,050 and the 100-hourly Simple Moving Average.
There is a short-term contracting triangle forming with support at $3,950 on the hourly chart of ETH/USD (data feed via Kraken).
The pair could continue to move up if it trades above $4,075.

Ethereum Price Dips To Support
Ethereum price struggled to settle above $4,200 and corrected most gains, like Bitcoin. ETH price declined below the $4,050 and $4,000 levels.

It even tested the $3,940 zone. A low was formed at $3,932 and the price is now consolidating losses. There was a minor increase above the 23.6% Fib retracement level of the recent decline from the $4,216 swing high to the $3,932 low.

Besides, there is a short-term contracting triangle forming with support at $3,950 on the hourly chart of ETH/USD. Ethereum price is now trading below $4,050 and the 100-hourly Simple Moving Average.

On the upside, the price could face resistance near the $4,075 level. The next key resistance is near the $4,150 level and the 76.4% Fib retracement level of the recent decline from the $4,216 swing high to the $3,932 low. The first major resistance is near the $4,200 level.

Source: ETHUSD on TradingView.com
A clear move above the $4,200 resistance might send the price toward the $4,250 resistance. An upside break above the $4,250 region might call for more gains in the coming sessions. In the stated case, Ether could rise toward the $4,350 resistance zone or even $4,420 in the near term.

Another Decline In ETH?
If Ethereum fails to clear the $4,150 resistance, it could start a fresh decline. Initial support on the downside is near the $3,950 level and the triangle’s trend line. The first major support sits near the $3,880 zone.

A clear move below the $3,880 support might push the price toward the $3,820 support. Any more losses might send the price toward the $3,750 region in the near term. The next key support sits at $3,640.

Technical Indicators

Hourly MACD – The MACD for ETH/USD is losing momentum in the bullish zone.

Hourly RSI – The RSI for ETH/USD is now below the 50 zone.

Major Support Level – $3,950

Major Resistance Level – $4,150

The company said it has since burned the excess tokens, and that the root cause of the incident has been addressed.

Ethereum could be one step closer to achieving 10,000 transactions per second, following the introduction of a new Ethereum scaling technology called Pico Prism. 

Ethereum scaling firm Brevis announced on Wednesday a new state-of-the-art zero-knowledge Ethereum Virtual Machine (zkEVM) for real-time proving. 

The technology can now prove Ethereum blocks almost instantly using regular retail gaming processors (GPUs) instead of expensive supercomputers.

“Brevis has achieved real-time proving of Ethereum L1 using consumer-grade hardware,” the firm stated, adding that it used 64 Nvidia RTX 5090 graphics cards, the current flagship model for gaming. 

In a test conducted in September, Pico Prism achieved 99.6% real-time proving in under 12 seconds. Real-time proving (RTP) means generating a cryptographic proof that a block was executed correctly faster than new blocks are being produced.

“This marks a major step toward scaling Ethereum by 100x and a future where you can validate the chain from a phone.”Pico Prism has turbocharged real-time proving. Source: Brevis
Brevis has a roadmap to achieve 99% real-time proving with fewer than 16 RTX 5090 GPUs “in the next couple of months.”

Big step toward Ethereum scalingThis breakthrough means that proving, which is computationally expensive, has finally caught up to block production speed using affordable consumer hardware, which makes lightweight validation practical for the first time.

Currently, every validator re-executes every transaction to verify blocks, which requires expensive hardware and creates a fundamental bottleneck, Brevis explained.

“Real-time proving breaks this model. One prover generates a proof, and everyone else verifies it in milliseconds.”The path to 10,000 TPSAccording to the Ethereum roadmap, validators will switch from re-executing transactions to simply verifying ZK-proofs, enabling the base layer to hit 10,000 transactions per second.

“At 3x per year, scaling Ethereum L1 would reach 10k TPS by April 2029,” said Ryan Sean Adams from Bankless. 

Ethereum’s Fusaka upgrade, expected in December, will simplify real-time proving, explained Bitcoin security researcher Justin Drake.

“EIP-7825 caps per transaction gas usage, enabling more parallel proving via subblocks,” he said before adding, “By year’s end, several teams will prove every L1 EVM block on a 16-GPU cluster, drawing less than 10kW total.”

Phone as a node future It is “one big step toward Ethereum’s future,” said the Ethereum Foundation, which added: 

“ZK technology like Pico Prism will enable Ethereum to scale to meet global demand, while still remaining trustworthy and decentralized.”“The phone-as-a-node future just got real,” said tech entrepreneur Mike Warner. 

Ethereum is transforming into a zk-chain, said Adams, who explained that layer-1 will run global DeFi, with big blocks at 10,000 TPS, and nodes that run on a phone, while layer-2 will run everything else.

It is essentially the holy grail of blockchain: massive scalability without sacrificing decentralization or security.

Magazine: Ethereum’s roadmap to 10,000 TPS using ZK tech: Dummies’ guide